

Special Issue

The Use of Antibiotics in COVID-19 Infections

Message from the Guest Editor

A recent report on the casualties related to antibiotic resistance by the World Health Organization (WHO) identified an alarming rate of 700,000 lives per year at present and predicts a disturbing 10 million/year by 2050, ensuring that antibiotic resistance will be the most prevalent cause of death. Adding to this, the WHO also forewarns the severity of antibiotic resistance, stating that “it threatens the achievements of modern medicine, a post-antibiotic era—in which common infections and minor injuries can kill—is a very real possibility for the 21st century”. Overuse or misuse of antibiotics recommended by physicians/self-medication at the time of infection have meant that drug-resistant pathogens become a major health care issue with millions of reported cases every year. With a pandemic such as COVID-19, the overuse of antibiotics can represent a critical point in fighting antimicrobial resistance. The unnecessary use of antibiotics can facilitate the spread of resistant pathogens, and the use of antibiotics in the management of a viral disease such as COVID-19 could have heavy implications for antimicrobial resistance response.

Guest Editor

Dr. Eleonora Nicolai

Departmental Faculty of Medicine, UniCamillus- Saint Camillus International University of Health and Medical Sciences, Via di S.Alessandro 8, 00132, Rome, Italy

Deadline for manuscript submissions

closed (31 December 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/99104

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)